Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Nasus Pharma Ltd. ( (NSRX) ) is now available.
On December 22, 2025, Nasus Pharma Ltd. released a shareholder letter from CEO Dan Teleman highlighting a transformational year marked by clinical, regulatory and financial milestones around its lead intranasal epinephrine candidate NS002. In early 2025 the company presented positive integrated data from two early clinical trials of NS002, completed a $10 million initial public offering in August that strengthened its balance sheet, expanded collaboration agreements in October with Aptar France S.A.S. and AptarGroup Inc. to use their commercial Unit Dose System device for NS002, and secured Health Canada authorization in October to start a Phase 2 study, in which the first patient has already been dosed in a trial comparing NS002 with EpiPen in up to 50 healthy adults with allergic rhinitis. The update underscores that these steps are intended to advance NS002 toward commercialization as a convenient, needle-free option for anaphylaxis and to support broader use of Nasus’s intranasal powder platform in emergency care, while setting the stage for key 2026 milestones including Phase 2 data, regulatory submissions and potential first-in-human studies for additional pipeline candidates.
The most recent analyst rating on (NSRX) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Nasus Pharma Ltd. stock, see the NSRX Stock Forecast page.
More about Nasus Pharma Ltd.
Nasus Pharma Ltd. is a clinical-stage pharmaceutical company focused on developing intranasal powder products for acute and emergency medical conditions in the community. Its lead candidate, NS002, is an intranasal epinephrine powder being developed as a fast-acting, needle-free alternative to traditional epinephrine autoinjectors for anaphylaxis, leveraging the company’s proprietary powder-based intranasal (PBI) Nasax technology for rapid, reliable drug absorption via the nasal cavity.
Average Trading Volume: 15,180
Technical Sentiment Signal: Strong Buy
For a thorough assessment of NSRX stock, go to TipRanks’ Stock Analysis page.